Search
Axicabtagene ciloleucel
go.drugbank.com/drugs/DB13915ApprovedInvestigationalThe drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. … [L40054] The development of resulted from early preclinical studies conducted by a group of researchers at the National Cancer Institute (NCI), who demonstrated that T cells expressing an anti-CD19 CAR
Synonyms: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptorSynthetic Conjugated Estrogens, A
go.drugbank.com/drugs/DB09317ApprovedThere is currently no generic form of CEEs available as a detailed analytical characterization of the active ingredients or of their estrogenic activity is not available at this time. … However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control
Synonyms: Estrogens, Conjugated Synthetic A, Synthetic Conjugated Estrogens, AMidomafetamine
go.drugbank.com/drugs/DB01454IllicitInvestigationalAn N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. … It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesLunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigational[L56135,L56136] This landmark decision followed designations as a Regenerative Medicine Advanced Therapy (RMAT) and Fast Track, marking the first-ever gene therapy approved to restore a neurosensory function … Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss.
Affitope AD01
go.drugbank.com/drugs/DB06086InvestigationalAD01 is a short peptide (7 amino acids in length) that induces Aß-targeting antibodies, therefore lowering Aß aggregates. … Affitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease.
Nortriptyline
go.drugbank.com/drugs/DB00540ApprovedInvestigationalNortriptyline hydrochloride, the active metabolite of [amitriptyline], is a tricyclic antidepressant (TCA).
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSynonyms: 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Δ5,γ-propylamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamineTafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigationalTafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. … [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.
Isaralgagene civaparvovec
go.drugbank.com/drugs/DB16808InvestigationalIsaralgagene civaparvovec, formerly known as ST-920, is liver-tropic rAAV 2/6 vector carrying the cDNA for human alpha-galactosidase A (α-Gal A) enzyme.
EGT-201
go.drugbank.com/drugs/DB17648ExperimentalEGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the alpha-N-acetyglucosaminidase (NAGLU) transgene.